Drug
Advisories
CMAJ
is committed to publishing advisories and warnings
of serious adverse drug reactions from Health
Canada and the US Food and Drug Administration
(FDA) as soon as they are available. In addition,
we regularly create practical, readable summaries
of the important information contained in some
advisory and warning letters. For more
information about drug reactions reported in Canada, see the Health
Canada Web site.
2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003
| ADVISORY |
FROM |
DATE
POSTED |
| ADHD drug atomoxetine (Strattera): potential for severe liver injury |
FDA |
Dec 22, 2004 |
| Increased cardiovascular events for patients taking naproxen in Alzheimer's trial |
FDA |
Dec 21, 2004 |
| Familial Adenomatous Polyposis celecoxib trial halted due to excess cardiovascular events |
HC |
Dec 21, 2004 |
| Pamidronate (Aredia) and/or zoledronic acid (zometa) and osteonecrosis of the jaw |
HC |
Dec 21, 2004 |
| FDA recall of CARDIAC REader System: false negative TnT and myoglobin results |
FDA |
Dec 16, 2004 |
| Valdecoxib (Bextra) not to be used in patients undergoing CABG CMAJ summary |
FDA |
Dec 14, 2004 |
| Valdecoxib (Bextra) and cardiovascular risk and serious skin reactions CMAJ summary |
HC |
Dec 14, 2004 |
| New hemoglobin targets for cancer patients using Epoetic (procrit) |
FDA |
Dec 10, 2004 |
| Lorazepam pills containing GLYBURIDE |
HC |
Dec 08, 2004 |
| FDA recall of Tosoh Bioscience AIA-600 II Enzyme Immunoassay Analyzer, software version 3.02 |
FDA |
Dec 08, 2004 |
| Inappropriate use of Bicillin C-R to treat syphilis |
FDA |
Dec 06, 2004 |
| Risk of rhabdomyolysis (muscle breakdown) for patients taking Crestor |
HC |
Nov 26, 2004 |
| Depo-Provera and bone density loss CMAJ summary |
FDA |
Nov 26, 2004 |
| FDA Recall of Access CardioSystems Automated External Defibrillators -failure to deliver shock |
FDA |
Nov 26, 2004 |
| Recall unused Advanced Bionics implantable cochlear stimulators |
HC |
Nov 11, 2004 |
| Safety Information on the LTV Series Ventilators |
FDA |
Nov 10, 2004 |
| Rheumatoid arthritis drugs Humira (adalimumab) and anakinra: serious reactions |
FDA |
Nov 10, 2004 |
| Recall of Oral-B CrossAction Power and PowerMAX toothbrushes and refills |
FDA |
Nov 2, 2004 |
| Cardiac valve problems and pergolide (Permax) |
HC |
Oct 27, 2004 |
| Eprex and vascular thrombotic events |
HC |
Oct 26, 2004 |
| Potassium supplement recall |
HC |
Oct 26, 2004 |
| Risk of serious infection from ultrasound medical gels
CMAJ summary |
HC |
Oct 26, 2004 |
| TNFa-blocking agents, including Remicade, increased cases of lymphoma in trials |
FDA |
Oct 13, 2004 |
| Rituxan (rituximab): Hepatitis B virus (HBV) reactivation with fulminant hepatitis, hepatic failure, and death in patients with hematologic malignancies |
FDA |
Oct 13, 2004 |
| Vioxx (rofecoxib) withdrawal from market regarding possible cardiovascular adverse events CMAJ summary |
HC |
Oct 06, 2004 |
| Levoxyl (levothyroxine): reports of choking and gagging on tablets stuck in throat |
FDA |
Oct 06, 2004 |
| Zometa (zoledronic acid) Injection: osteonecrosis of the jaw |
FDA |
Oct 01, 2004 |
| Recall of LTV series of ventilators, models 1000, 950, 900 and
800: battery failure |
FDA |
Oct 01, 2004 |
| Voluntary withdrawal of Vioxx (rofecoxib) CMAJ summary |
FDA |
Oct 01, 2004 |
| LAMICTAL (lamotrigine) levels decreased on oral contraceptives |
HC |
Sept 29, 2004 |
| FDA recall of infusion pump Medtronic Model 8870 software application cards |
FDA |
Sept 27, 2004 |
| Cracking Protonix I.V. for Injection vials |
FDA |
Sept 27, 2004 |
| Nellcor CapnoProbe Sublingual Sensors Recall |
FDA |
Sept 27, 2004 |
| Class I recall of the Minerva Patient Lift (models ML-20 and ML-30) |
FDA |
Sept 2, 2004 |
| Health Canada Advises Consumers to Return Euro-K and Riva-K Potassium Chloride Products |
Health Canada |
Sept 3, 2004 |
| Important Safety Information on
Euro-K and Riva-K Sustained Release Potassium Supplements |
Health Canada |
Sept 2, 2004 |
| Geodon (ziprasidone) associated with increased risk of hyperglycemia and diabetes |
FDA |
Sept 1, 2004 |
| Remicade (infliximab) associated with leukopenia, neutropenia, pancytopenia, and systemic vasculitis |
FDA |
Aug 24, 2004 |
| Low molecular weight heparin enoxaparin sodium (lovenox) requires dosage adjustment in severe renal impairment |
FDA |
Aug 17, 2004 |
| Chemotherapeutic bevacizumab (Avastin) associated with increased risk of serious arterial thromboembolic events |
FDA |
Aug 17, 2004 |
| US Tracheostomy Tube and Cannula recall |
FDA |
Aug 10, 2004 |
| Potential adverse effects of SSRIs and other anti-depressants on newborns |
Health Canada |
Aug 10, 2004 |
| Possible Association of RITUXAN (rituximab) with Hepatitis B Reactivation |
Health Canada |
Aug 3, 2004 |
| Patients not to use Aristolochic Acid derivatives over concerns of cancer, kidney failure CMAJ summary |
Health Canada |
July 28, 2004 |
| Patients to not use sesa hair supplement capsules due to unacceptable levels of lead |
Health Canada |
July 28, 2004 |
| Recall of the Hepatitis B and C tests: Roche COBAS TaqMan and TaqMan 48 Analyzer |
FDA |
July 27, 2004 |
| FDA recall of Boston Scientific Express2TM coronary stents |
FDA |
July 27, 2004 |
| FDA Recall of Troponin Test kits -VITROS Troponin I Reagent Pack |
FDA |
July 27, 2004 |
| FDA recall of two lots of Taxus eluting coronary stents |
FDA |
July 15, 2004 |
| FDA recall of Arjo Alenti Lift hygiene chair |
FDA |
July 15, 2004 |
| FDA recall of VISULINK 532/U medical device |
FDA |
July 15, 2004 |
| Potential trazodone interactions |
Health Canada |
July 13, 2004 |
| Rheumatoid Arthritis treatment leflunomide (Arava) and interstitial lung disease |
Health Canada |
June 29, 2004 |
| CIDEX OPA instrument sterilization solution: contraindicated for reprocessing of urological instruments used on patients with a history of bladder cancer |
Health Canada |
June 29, 2004 |
| Pharmacists must ensure that patients on different clozapine brands, have updated registries |
Health Canada |
June 29, 2004 |
| Concerns that neonates exposed to SSRIs, SNRIs in 3rd trimester may develop Serotonin-syndrome-like symptoms at birth |
FDA |
June 29, 2004 |
| Rosuvastatin (Crestor) and rhabdomyolysis CMAJ summary |
Health Canada |
June 24, 2004 |
| Recall of Penicillin allergy test: PRE-PEN (benzylpenicilloyl polylysine injection) |
Health Canada |
June 22, 2004 |
| Risk factors for crestor (rosuvastatin) associated myopathy CMAJ summary |
FDA |
June 15, 2004 |
| Recall of the Tecan Clinical Workstation (TCW) used in the detection of gonorrhea and chlamydia |
FDA |
June 15, 2004 |
| Hemodialysis treatment and potential for patient to patient cross contamination |
Health Canada |
June 15, 2004 |
| Recall of Proglycem hypoglycemic treatments |
Health Canada |
June 8, 2004 |
| Potential for self harm/suicide in users of SSRIs and newer antidepressants- Luvox (fluvoxamine maleate) |
Health Canada |
June 3, 2004 |
| Potential for self harm/suicide in users of SSRIs and newer antidepressants- Paxil (paroxetine) |
Health Canada |
June 3, 2004 |
| Potential for self harm/suicide in users of SSRIs and newer antidepressants- Zoloft sertraline hydrochloride) |
Health Canada |
June 3, 2004 |
| Potential for self harm/suicide in users of SSRIs and newer antidepressants- Remeron RD & Remeron (mirtazapine) |
Health Canada |
June 3, 2004 |
| Potential for self harm/suicide in users of SSRIs and newer antidepressants- Prozac (fluoxetine hydrochloride) |
Health Canada |
June 3, 2004 |
| Potential for self harm/suicide in users of SSRIs and newer antidepressants- Effexor / Effexor XR (venlafaxine) |
Health Canada |
June 3, 2004 |
| Potential for self harm/suicide in users of SSRIs and newer antidepressants- Celexa (citalopram hydrobromide) |
Health Canada |
June 3, 2004 |
| Patients warned to not use over-the-counter weight loss product Thermonex |
Health Canada |
June 1, 2004 |
| FDA recall of Quick-set Plus insulin infusion pumps |
FDA |
May 25, 2004 |
| Trazodone (desyrel): potential for drug interactions with CYP3A4 inhibitors ketoconazole, ritonavir, and indinavir |
FDA |
May 18, 2004 |
| Muromonab-CD3 (Orthoclone OKT*3) transplant antirejection drug:cerebral edema, lymphomas |
Health Canada |
May 18, 2004 |
| Diarrhea and Ischemic Colitis in Patients Using tegaserod hydrogen maleate (ZELNORM) |
Health Canada |
May 11, 2004 |
| Zelnorm (tagserod maleate) and diarrhea and ischemic colitis CMAJ summary |
FDA |
May 4, 2004 |
| Inadequate sterilization of acetabular reamer |
Health Canada |
April 27, 2004 |
| Recall of Medtronic implantable cardioverter defibrillators (ICDs) |
FDA |
April 22, 2004 |
| Asthma drug zafirlukast (Accolate) and serious hepatic adverse events CMAJ summary |
Health Canada |
April 20, 2004 |
| Concerns about infusion pumps |
Health Canada |
April 20, 2004 |
| Olanzapine (Zyprexa): increased incidence of cerebrovascular events in dementia trials CMAJ summary |
Health Canada |
April 13, 2004 |
| FDA fentanyl patch (duragesic) recall |
FDA |
April 13, 2004 |
| Clozapine (Clozaril) and increased risk of hyperglycemia and diabetes |
FDA |
April 13, 2004 |
| Atypical antipsychotic aripiprazole (Abilify) and hyperglycemia and diabetes |
FDA |
April 13, 2004 |
| Recall of Human Rabies Vaccine IMOVAX (Aventis Pasteur) |
FDA |
April 6, 2004 |
| Absorbable hemostatic agents during surgery: ways to reduce paralysis and neural deficits |
FDA |
April 6, 2004 |
| Incorrect lot number listed for Vitek antibiotic susceptibility test cards |
FDA |
April 6, 2004 |
| FDA recalls some bacterial susceptibility testing cards |
FDA |
Mar 30, 2004 |
| FDA warns of worsening of suicidality in some patients taking antidepressants |
FDA |
Mar 24, 2004 |
| Olanzepine (Zyprexa) and Hyperglycemia CMAJ summary |
FDA |
Mar 23, 2004 |
| Olazepine (Zyprexa) and Strokes in the Elderly CMAJ summary |
Health Canada |
Mar 23, 2004 |
| Piperacillin/tazobactam association with false
positive results on an Aspergillus Assay |
Health Canada |
Mar 16, 2004 |
| Failure of Faaborg battery operated patient lifts: Recall due to serious injuries, death |
FDA |
Mar 16, 2004 |
| Fetanyl
transdermal patches (Duragesic) Recall in
US for manufacturing defect |
FDA |
Feb
24, 2004 |
| HIV
drug Neviramine (Viramune) and hepatic toxicity,
rash CMAJ summary |
Industry |
Feb
19, 2004 |
| Pergolide
(Permax): Sudden onset of sleep in Parkinsonian
patients CMAJ summary |
Health
Canada |
Feb
19, 2004 |
| Counterfeit
Contraceptive patches |
FDA |
Feb
10, 2004 |
| Severe
life-threatening reactions to nevirapine
(Viramune) CMAJ summary |
FDA |
Feb
3, 2004 |
| Fluticasone
propionate (Flonase/Flovent/Advair) and
ritonavir (Norvir/Kaletra) interaction |
Health Canada |
Feb
3, 2004 |
| Oseltamivir
(Tamiflu) unsafe in infants under 1 year
old CMAJ summary |
FDA |
Jan
27, 2004 |
| Epoetin
alpha (Eprex): Do not give it subcutaneously |
Health
Canada |
Jan
20, 2004 |
| Smoke/fire
in anesthesia machines using sevoflurane
(SEVORANE AF) and desiccated carbon dioxide
(CO2) absorbent |
Health
Canada |
Jan
13, 2004 |
| False
results with the HBsAg ELISA System 3 Confirmatory
Test |
FDA |
Jan
13, 2004 |
| Serious
liver injury with use of pyrazinamide (Tebrazid)
and rifampin for latent TB |
Health
Canada |
Jan
13, 2004 |
| Oseltamivir
(Tamiflu) not to be used in children less
than 1 year CMAJ summary |
FDA |
Jan
7, 2004 |
| Strangulation
of infants by IV tubing and monitor leads
|
Health
Canada |
Jan
6, 2004 |
|